Inserm presentation
Contents

• Address major biomedical research challenges

• Take action to improve the health of all

• Disseminate knowledge for the benefit of all
Address major biomedical research challenges
Address major biomedical research challenges

Be a reference in biomedical research

In Europe and worldwide
- 7,000 international cooperation agreements with 106 countries
- 2 thematic coordination programs, 12 new first-step projects and 12 new European and international research projects or networks
- 2 joint research units abroad

In France
- 269 research units
- 34 clinical investigation centers
- 48 service units

14,180 staff
- 5,025 civil servants (2,166 researchers, ATIP-Avenir contracts included)
- 3,423 contract staff and temporary workers (incl. ATIP-Avenir contracts)
  > 50 ATIP-Avenir contracts
- 5,732* teacher-researchers and hospital teachers

A budget of €1,060 million
€681 million from government subsidies and €379 million from internal resources

Patents and licenses
- A portfolio of 2,321 patent families
- 126 new license agreements signed
- 307 R&D partnerships

* As of April 7, 2023
• Address major biomedical research challenges

Be a reference in biomedical research (2)

In Europe
• No. 1 academic applicant in the biomedical sector in Europe
• No. 2 European applicant in the biotechnology sector
• No. 2 European applicant in the pharmaceutical sector

Horizon Europe launch and 2021 results:
• ERC: 17 individual grants, 2 participations in Synergy Grants
• Marie Skłodowska Curie Actions: 5 individual grants, 3 doctoral networks, including 1 coordination
• Health Cluster: 11 projects funded, including 3 coordinations
• EIC: 5 projects, including 1 coordination

Horizon 2020 results:
• 1st coordinator of the Health societal challenge
• 396 contracts, including 83 grant recipients and 53 Marie Skłodowska-Curie individual grants

Close dialogue
with over 500 patient organizations for
• participatory research
• meetings and debates between patients and researchers

11,936 original articles
Address major biomedical research challenges

Make changes to adapt

1964
Inserm is created

1983
Inserm is created
Public scientific and technological institute, entirely dedicated to human health and biomedical research
Placed under the joint authority of the French Ministries of Health and Research

2009
Inserm, following reform, ensures the strategic, scientific and operational coordination of biomedical research
Aviesan, the French National Alliance for Life Sciences and Health, is created

2011

2014
Inserm establishes its 2025 Strategic plan with the French State
Inserm celebrates its 50th anniversary

2019
Inserm establishes its 2021-2025 Objectives, resources and performance contract

2022
Inserm establishes its 2025 Strategic plan with the French State
Address major biomedical research challenges

Our organization

Thematic Institutes
- Neurosciences, Cognitive Sciences, Neurology, Psychiatry
- Cancer
- Immunology, Inflammation, Infectious Diseases and Microbiology
- Pathophysiology, Metabolism, Nutrition
- Public Health
- Health Technologies
- Molecular and Structural Basis of Living Organisms
- Cell Biology, Development and Evolution
- Genetics, Genomics and Bioinformatics

Divisions
- Financial Affairs
- Legal Affairs
- Program Assessment and Follow-Up
- Scientific Information and Communication
- Partnership and External Relations
- Human Resources
- Information Systems
- Chief Accounting Department

Regional Offices
- Île-de-France (4)
- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Occitanie Méditerranée
- Occitanie Pyrénées
- Nord-Ouest
- Nouvelle-Aquitaine
- Provence, Alpes, Côte d’Azur and Corsica
Address major biomedical research challenges

Our presence in France

269 research units

48 service units

34 clinical investigation centers
Our presence in France (2)

85% of Inserm strengths

14 research universities in which Inserm invests more than €10M each year
Our main partners

- **35** universities

- A key partner of **14** research universities in which Inserm invests more than €10M each year

- On **14** Idex and I-sites, Inserm invests **72%** of its resources

- Research units in **29** teaching hospitals

- Founding members of Aviesan alongside Inserm: CEA / CNRS / INRAE / INRIA / Institut Pasteur / IRD / CPU / CHRU and the associate members

- Other alliances: AllEnvi, Allistène, Athéna

- Industry: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi…

- Foundations and associations: Fondation Bettencourt Schueller, FRM…

- European and international academic institutions: Helmholtz…
Our presence in Europe

- Research teams: informal **scientific cooperation** with their partners
- Institutional **partnership agreements** and specific **collaborative networks** in Europe: 5 European laboratories within 2 thematic coordination programs, 12 leading international research projects (IRP), 2 within a single international research network (IRN), and 9 leading first step projects
• Address major biomedical research challenges

Our presence in the world

• Research teams: informal **scientific cooperation** with their partners
• Institutional **partnership agreements** and **specific collaborative networks** outside Europe: 3 non-European laboratories within 2 thematic coordination programs, 19 leading international research projects (IRP), 1 within an international research network (IRN), and 3 first step projects
Take action to improve the health of all
Our missions for health

- Take action to improve the health of all

**INITIATE, DEVELOP AND COORDINATE BIOMEDICAL RESEARCH OF EXCELLENCE**

- Produce and disseminate knowledge nationally and internationally
- Play a major role in the national coordination of health research
- Support higher education and research training
- Provide scientific expertise and support for science based policy in health
- Create value from discoveries and their applications
Our fields of activity and expertise

- Fundamental research
- Clinical and preclinical trials
- Cohorts and epidemiological studies
- Provision of expertise and contribution to public health and research policy
- Biomedical research infrastructure
- Technology transfer
Cohorts and epidemiological studies

- **EpiCOV**: 130,000 volunteers for research on SARS-CoV-2
- **ELFE**: 20,000 children born in 2011, longitudinal study from birth to adult age
- **Constances**: 220,000 subjects representative of the French population, aged 18 to 69 years on inclusion + a biobank of 100,000 subjects
- **RaDiCo**: over 5,000 people with rare diseases in 12 cohorts
- Over **1.6 million people** (2% of the French population) participating in Inserm cohorts

**Major public health expertise and research databases, accessible online**

- **Epidemiologie-France portal**: French health database catalogue
  > epidemiologie-france.aviesan.fr
- **CépiDc**: Epidemiology center on the medical causes of death
  > cepidc.inserm.fr
- **Orphanet**: Portal for rare diseases and orphan drugs
  > orpha.net

Over **1.6 million people** participating in Inserm cohorts
Take action to improve the health of all

A continuum from basic to clinical, therapeutic, and public health research

- Basic research
- Preclinical Studies Proof of concept
- Phases I, IIa, IIb, III
- Phase IV

- 269 research units
- National research infrastructures
- 34 clinical research centers
- About 90 cohorts & large scale studies
• Take action to improve the health of all

Value creation activities which are bearing fruit

- **2,321** patent families portfolio
- **160** new patent families in 2022
- An annual budget of **€1.8 M** to fund project maturation or proof of concept
- A maturation budget reaching **€23.3 M** invested in 336 projects since 2009
- **€495.5 M** industrial partnerships since 2010 (patents, research contracts)
- **€15-20 M** per year from licensing agreements
- Over **400** technologies and research tools available for licensing
- Strategic alliances with, for example: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi
- 10 startups created each year via Inserm Transfert (Inserm’s subsidiary)
- Partnerships with SATTs
Take action to improve the health of all

Inserm & Inserm Transfert in EPO rankings

- No. 2 European applicant in the pharmaceutical sector (in the Top 3 since 2015)*
- No. 2 European applicant in the biotechnology sector (4th year)*
- No. 1 European research academic institution in the biomedical sector*
- 2,321 patent families as of 31/12/2022

* European Patent Office (EPO) 2022 rankings
Take action to improve the health of all

Inserm Transfert: partnering with industries

SOME OF OUR INDUSTRIAL PARTNERS: Privileged partner of major industrials, mid-size, SME, involved in human health, at the international level

- Roche
- MedImmune
- Baxter
- FreseNIUS
- Janssen
- ultragenyx
- TRi
- AstraZeneca
- abbvie
- sanofi
- Quest Diagnostics
- Boehringer Ingelheim
- Gilead
- QIAGEN
- Bristol Myers Squibb
- MSD
- Shire
- Amgen
- OtsuKc
- Inserm
● Take action to improve the health of all

Inserm spin-offs based on inventors as drivers
Major discoveries

Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- the first prenatal diagnostic tests;
- understanding the HLA system and the ensuing immune reactions;
- the first in vitro fertilization;
- identification of HIV;
- radiotherapy for cancer;
- the first skin graft;
- deep brain stimulation in the treatment of Parkinson’s disease;
- gene therapy…
Disseminate knowledge for the benefit of all
Collective expert reviews and contribution to public health policy

Inserm fulfils its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.
Our work with patient organizations

Towards research in partnership with patient organizations and civil society collectives

- Promote meetings and direct dialogue between researchers and collectives
- Act for the structuring, coordination and animation of participatory research projects
- Help to better take into account these projects in the assessment of researchers and structures
- Facilitate access to scientific information for society
Our presence in the service of public information

- **Disseminate knowledge for the benefit of all**

<table>
<thead>
<tr>
<th>platform</th>
<th>count</th>
<th>followers/followers</th>
<th>participants/views</th>
</tr>
</thead>
<tbody>
<tr>
<td>inserm.fr</td>
<td>12,596,000</td>
<td>12,596,000</td>
<td>sessions</td>
</tr>
<tr>
<td>LinkedIn</td>
<td>131,000</td>
<td>131,000</td>
<td>followers</td>
</tr>
<tr>
<td>Twitter</td>
<td>158,000</td>
<td>158,000</td>
<td>followers</td>
</tr>
<tr>
<td>Facebook</td>
<td>51,000</td>
<td>51,000</td>
<td>followers</td>
</tr>
<tr>
<td>Instagram</td>
<td>13,000</td>
<td>13,000</td>
<td>followers</td>
</tr>
<tr>
<td>YouTube</td>
<td>339,000</td>
<td>339,000</td>
<td>followers</td>
</tr>
<tr>
<td>Mag</td>
<td>30,500</td>
<td>30,500</td>
<td>followers</td>
</tr>
</tbody>
</table>

- **Live lectures and 30’ Santé broadcast**
  - 34,500 views

- **Public events**
  - 1.8 million participants and views

- **Meetings on participatory research**
  - 250 participants

- **Canal Détox information videos and articles**
  - 277,000 views